About AxioMx
AxioMx is a Healthcare company based in Branford (United States) founded in 2012 by Christopher McLeod, and was acquired by Abcam in November 2015. A recombinant antibody discovery and development platform is operated. AxioMx has raised $4.11 million across 8 funding rounds from investors including Abcam, NIH and HHS. Its chief executive, as recorded, is Christopher McLeod. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Proteomics. Its competitors include Somalogic, Nautilus Biotechnology and Amunix; 3 of its 3 listed competitors have raised funding.
Company details
AxioMx was founded in 2012 in Branford, United States, within the biotechnology sector. A platform for recombinant antibody discovery and development services is maintained, featuring phage display libraries, screening, and affinity maturation techniques to shorten antibody development timelines. Services encompass recombinant antibody development, optimization, antigen design, and project planning. The company was acquired by Abcam in 2015.
- Headquarters Branford, United States
- Founders Christopher McLeod
- Stage Acquired
- SectorsHealthcare
- Website axiomxinc.com
- Acquired by Abcam (Nov 2015)
Funding Insights of AxioMx
AxioMx has successfully raised a total of $4.11M across 8 strategic funding rounds. The most recent funding activity was a Grant round of $216 thousand completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.11M
- Total Rounds 8
- Last Round Grant — $216,000
- First Round $2.11M
(Nov 2012)
- Investors Count 5
All 8 funding rounds of AxioMx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2015 | $216,000 | Grant | – | – | |
| Mar 2015 | Grant | – | – | ||
| Feb 2015 | $220,323 | Grant | – | – | |
| Sep 2014 | $218,694 | Grant | – | – | |
| Sep 2014 | $222,500 | Grant | – | – | |
| Oct 2013 | $2M | Seed | – | – | |
| Jul 2013 | $1.61M | Grant | – | – | |
| Nov 2012 | $2.11M | Seed | – | Connecticut Innovations, Elm Street Ventures | – |
6 investors in total: 6 institutional.
Investors in AxioMx
AxioMx has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Abcam, NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | ctinnovations.com | |||
VC firm investing in seed & early stage companies in the US | 2006 | elmvc.com | New Haven, United States | |
Private investments are made in early and later-stage businesses. | 2017 | vitalvc.com | Washington, DC, USA | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Biological reagents and antibodies are developed for life science research. | 1998 | abcam.com | Cambridge, United Kingdom |
Investor details for AxioMx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AxioMx
1 people are tracked at AxioMx (1 in leadership).
| Name | Role | Group |
|---|---|---|
Christopher McLeod | Co-Founder & CEO | Leadership |
Complete people profiles for AxioMx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AxioMx
4 dated milestones of AxioMx across 3 years, from founding to its latest funding, stage changes and deals.
- Founded AxioMx is founded.
- Funding First funding round of $2.1M.
- Funding Latest funding round, Grant, of $216K.
- Exit Acquired by Abcam.
Competitors of AxioMx
AxioMx has 3 listed competitors in our database, 3 of them funded. They include Somalogic, Nautilus Biotechnology and Amunix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| somalogic.com | 1999 | Boulder, United States | $663.99M | 319 | Protein-based assays are developed for life science research. | |
| nautilus.bio | 2016 | Seattle, United States | $103.26M | 134 | A proteomics platform is developed for analyzing the human proteome. | |
| amunix.com | 2006 | Mountain View, United States | $200.59M | 82 | Peptide-based therapeutics are developed for cancers and immune disorders. |
Detailed competitors of AxioMx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as AxioMx (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AxioMx
AxioMx was founded in 2012.
AxioMx is headquartered in Branford, United States. It is registered at Branford, Connecticut, United States.
Christopher McLeod is the CEO of AxioMx, as recorded in our data. They have also founded this company.
AxioMx is a funded company, having raised a total of $4.11M across 8 funding rounds to date. The company's 1st funding round was a Seed of $2.11M, raised on Nov 2012.
AxioMx was founded in 2012 in Branford, United States, within the biotechnology sector. A platform for recombinant antibody discovery and development services is maintained, featuring phage display libraries, screening, and affinity maturation techniques to shorten antibody development timelines. Services encompass recombinant antibody development, optimization, antigen design, and project planning. The company was acquired by Abcam in 2015.
AxioMx's top competitors include Somalogic, Nautilus Biotechnology and Amunix.
AxioMx has 6 investors. Key investors include Abcam, NIH, HHS, Elm Street Ventures, and Connecticut Innovations.
Yes. AxioMx was acquired by Abcam in November 2015.